MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuances
of common stock and...
$53,577K
(-59.81%↓ Y/Y)
Proceeds from exercise of
stock options
$230K
(6.98%↑ Y/Y)
Proceeds from maturities
of...
$171,925K
(100.34%↑ Y/Y)
Net cash provided by
financing activities
$53,807K
(-59.70%↓ Y/Y)
Net cash provided by
(used in) investing...
$10,793K
(115.35%↑ Y/Y)
Canceled cashflow
$161,132K
Net change in cash
and cash...
$2,259K
(-85.83%↓ Y/Y)
Canceled cashflow
$62,341K
Stock-based compensation
$10,451K
(-20.36%↓ Y/Y)
Accounts payable,
accrued expenses and...
$6,724K
(-13.25%↓ Y/Y)
Prepaid expenses and
other assets
-$1,241K
(4.39%↑ Y/Y)
Non-cash lease expense
$313K
Deferred tax provision
$5K
(-98.84%↓ Y/Y)
Purchase of
available-for-sale short-term...
$161,132K
(3.20%↑ Y/Y)
Net cash used in
operating activities
-$62,341K
(-31.88%↓ Y/Y)
Canceled cashflow
$18,734K
Change in fair value of
warrant liabilities
-$33,449K
Other income, net
$4,220K
(7.54%↑ Y/Y)
Tegoprubart - other
development programs
-$168K
(-154.90%↓ Y/Y)
Net income (loss)
-$45,617K
(-26.07%↓ Y/Y)
Change in fair value of
warrant liabilities
-$33,449K
Canceled cashflow
$37,837K
Accretion of investment
discounts
-$1,696K
(39.41%↑ Y/Y)
Operating lease
liabilities
-$313K
(7.67%↑ Y/Y)
Tegoprubart - kidney
transplantation programs
$35,994K
(31.12%↑ Y/Y)
Manufacturing
$14,974K
(20.29%↑ Y/Y)
Personnel-related expenses
$14,526K
(35.68%↑ Y/Y)
Stock-based compensation
$10,451K
(-20.36%↓ Y/Y)
Other segment items
$7,474K
Provision for income taxes
$35K
(-91.88%↓ Y/Y)
Back
Back
Cash Flow
source: myfinsight.com
Eledon Pharmaceuticals, Inc. (ELDN)
Eledon Pharmaceuticals, Inc. (ELDN)